FDA feedback sets new open-label vatiquinone registration study for Q3 2026
FDA feedback sets new open-label vatiquinone registration study for Q3 2026, on May 7, 2026. A company milestone for PTC (vatiquinone for Friedreich's ataxia): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
- Company
- PTC Therapeutics, Inc. PTCT
- Drug
- vatiquinone
- For
- Friedreich's ataxia
- Stage
- Regulatory (NDA resubmission path)
- When
- May 7, 2026
- Source note
- PTC disclosed the outcome of an April 2026 Type C meeting with FDA on the path to an NDA resubmission for vatiquinone in Friedreich's ataxia: the company will run a new open-label study with a matched natural history control, starting Q3 2026, with mFARS change at 24 months as the primary endpoint.
- Checked
- Checked by a person when it was added
- Source: ir.ptcbio.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- PTCT headlines on this site
FDA engagement on votoplam PIVOT-HD 24-month results in Huntington's disease, expected in the second half of 2026 (no exact date yet). A company milestone for PTC (votoplam (PTC518) for Huntington's disease): a step in the program rather than a decision or a data readout.
More details
- Entry
- FDA engagement on votoplam PIVOT-HD 24-month results in Huntington's disease · Company milestone
- Drug
- votoplam (PTC518)
- For
- Huntington's disease
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Company plans to engage with FDA in 2H 2026 to discuss PIVOT-HD 24-month results; outcome frames a potential accelerated path for the Novartis-partnered program.
- Checked
- Checked by a person when it was added
- Verify it
- Source: prnewswire.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- PTCT headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
PTC303 (MSH3 splicing) clinical entry, expected during 2027 (no exact date yet). A company milestone for PTC (PTC303 for somatic expansion disorders (Huntington's disease, myotonic dystrophy)): a step in the program rather than a decision or a data readout.
More details
- Entry
- PTC303 (MSH3 splicing) clinical entry · Company milestone
- Drug
- PTC303
- For
- somatic expansion disorders (Huntington's disease, myotonic dystrophy)
- Stage
- Phase 1 · an early safety study in a small group of people
- When
- 2027 · the company gave a window, not a day
- Source note
- Company plans to enter the clinic in 2027 (year-level guidance only).
- Checked
- Checked by a person when it was added
- Verify it
- Source: prnewswire.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- PTCT headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page